- 1Q Net Sales for M3 Inc. were 86.20 billion yen, exceeding expectations with a 34% increase year-over-year.
- Operating income reached 19.78 billion yen, marking a 17% rise from the previous year and surpassing the anticipated 17.79 billion yen.
- Net income for the first quarter was 11.84 billion yen, a 5.3% improvement over last year, beating the estimate of 11.33 billion yen.
- For the first half of the year, M3 Inc. maintains its forecasts with expected:
- Operating income of 31.00 billion yen
- Net income at 18.50 billion yen
- Net sales projected to reach 172.00 billion yen
- Looking towards 2026:
- The company maintains its outlook for operating income at 70.00 billion yen, compared to an estimate of 71.97 billion yen.
- Net income is projected at 45.00 billion yen, slightly below the estimate of 46.5 billion yen.
- Net sales are anticipated to total 360.00 billion yen, outperforming the estimate of 356.03 billion yen.
- The company’s stock is currently rated with 7 buys, 9 holds, and 0 sells by analysts.
M3 Inc on Smartkarma
An independent investment analyst, Shifara Samsudeen, FCMA, CGMA, recently published a research report on M3 Inc on Smartkarma. In the report titled “M3: ELAN Acquisition Drives Top Line Growth; Earnings Growth to Remain Weak,” Shifara highlights that m3’s 3Q earnings exceeded estimates, with a significant portion of the top-line growth attributed to the ELAN acquisition. Despite an improvement in earnings trend, Shifara anticipates that growth will remain weak for M3 Inc. The company reported growth in both revenue and operating profit year-over-year, surpassing consensus estimates. However, the Medical Platform’s earnings have been on a declining trend due to pharmaceutical spending cuts, while Overseas earnings showed a slight improvement. Shifara cautions that although the overall decline in m3’s earnings has eased, weak earnings growth is expected with ELAN’s margins deteriorating.
A look at M3 Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 2 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on Smartkarma Smart Scores, M3 Inc‘s long-term outlook seems to be moderately positive. While the company has average scores in terms of value, dividend, and growth, it excels in resilience and momentum, scoring 4 out of 5 in both categories. This suggests that M3 Inc is well-positioned to weather market fluctuations and has a strong upward momentum in terms of performance.
M3 Inc, a provider of medical information services for doctors via the Internet, also assists in the marketing of pharmaceutical companies and medical equipment manufacturers. With a solid resilience score of 4 and a promising momentum score of 4, the company appears to have a robust foundation for long-term success and growth in the healthcare sector.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
